Redefining the Risk of Surgery for Clinical Stage IIIA (N2) Non-Small Cell Lung Cancer: A Pooled Analysis of the STS GTSD and ESTS Registry.
Aged
Carcinoma, Non-Small-Cell Lung
/ pathology
Databases, Factual
Female
Follow-Up Studies
Humans
Incidence
Lung Neoplasms
/ pathology
Male
Middle Aged
Neoplasm Staging
/ methods
Pneumonectomy
/ adverse effects
Postoperative Complications
/ epidemiology
Prospective Studies
Registries
Survival Rate
/ trends
United States
/ epidemiology
Journal
Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
12
01
2021
accepted:
07
04
2021
pubmed:
29
4
2021
medline:
24
12
2021
entrez:
28
4
2021
Statut:
ppublish
Résumé
Management of clinical stage IIIA-N2 (cIIIA-N2) non-small cell lung cancer (NSCLC) remains controversial. We evaluated treatment strategies and outcomes in cIIIA-N2 NSCLC patients who underwent pulmonary resection in The Society of Thoracic Surgeons General Thoracic Surgery Database (STS GTSD) and the European Society of Thoracic Surgeons (ESTS) Registry. The STS GTSD and ESTS Registry were queried for patients who underwent pulmonary resection for cIIIA-N2 NSCLC between 2012 and 2016. Demographic variables, treatment strategies, and outcome measures were collected and analyzed. Significance of differences was determined using the χ Pulmonary resection was performed in 4279 cIIIA-N2 NSCLC patients (2928 STS GTSD; 1351 ESTS). Induction therapy was administered to 49%. Lobectomy was performed in 67.1% and pneumonectomy in 13%. Lobectomy was associated with 19.2% major morbidity and 1.6% operative mortality, while pneumonectomy was associated with 34.1% and 5%, respectively. Induction therapy was associated with a higher rate of major morbidity or mortality than upfront surgery (23.2% vs 19.5%, p = 0.004), driven by pneumonectomy (40.7% vs 30.3%, p = 0.012) rather than lobectomy (20.3% vs 18.8%, p = 0.31). Pulmonary resection for cIIIA-N2 NSCLC is associated with low rates of operative morbidity and mortality, with lobectomy having lower morbidity and mortality than pneumonectomy. Induction therapy, particularly chemoradiotherapy, is associated with a higher rate of composite morbidity or mortality than upfront surgery in pneumonectomy patients but not lobectomy patients.
Sections du résumé
BACKGROUND
Management of clinical stage IIIA-N2 (cIIIA-N2) non-small cell lung cancer (NSCLC) remains controversial. We evaluated treatment strategies and outcomes in cIIIA-N2 NSCLC patients who underwent pulmonary resection in The Society of Thoracic Surgeons General Thoracic Surgery Database (STS GTSD) and the European Society of Thoracic Surgeons (ESTS) Registry.
METHODS
The STS GTSD and ESTS Registry were queried for patients who underwent pulmonary resection for cIIIA-N2 NSCLC between 2012 and 2016. Demographic variables, treatment strategies, and outcome measures were collected and analyzed. Significance of differences was determined using the χ
RESULTS
Pulmonary resection was performed in 4279 cIIIA-N2 NSCLC patients (2928 STS GTSD; 1351 ESTS). Induction therapy was administered to 49%. Lobectomy was performed in 67.1% and pneumonectomy in 13%. Lobectomy was associated with 19.2% major morbidity and 1.6% operative mortality, while pneumonectomy was associated with 34.1% and 5%, respectively. Induction therapy was associated with a higher rate of major morbidity or mortality than upfront surgery (23.2% vs 19.5%, p = 0.004), driven by pneumonectomy (40.7% vs 30.3%, p = 0.012) rather than lobectomy (20.3% vs 18.8%, p = 0.31).
CONCLUSIONS
Pulmonary resection for cIIIA-N2 NSCLC is associated with low rates of operative morbidity and mortality, with lobectomy having lower morbidity and mortality than pneumonectomy. Induction therapy, particularly chemoradiotherapy, is associated with a higher rate of composite morbidity or mortality than upfront surgery in pneumonectomy patients but not lobectomy patients.
Identifiants
pubmed: 33909135
doi: 10.1007/s00408-021-00447-5
pii: 10.1007/s00408-021-00447-5
doi:
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
311-318Références
Siegel R, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30
doi: 10.3322/caac.21442
Noone AM, Howlader N, Krapcho M et al (2018) SEER cancer statistics review, 1975–2015, National cancer institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/ , based on November 2017 SEER data submission, posted to the SEER web site
Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11(1):39–51
doi: 10.1016/j.jtho.2015.09.009
Veeramachaneni NK, Fein RH, Stephenson BJK, Edwards LJ, Fernandez FG (2012) Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg 94:922–928
doi: 10.1016/j.athoracsur.2012.04.087
Seder CW, Salati M, Kozower BD et al (2016) Variation in pulmonary resection practices between the society of thoracic surgeons and the European society of thoracic surgeons general thoracic surgery databases. Ann Thorac Surg 101(6):2077–2084
doi: 10.1016/j.athoracsur.2015.12.073
Albain KS, Swann RS, Rusch VW et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374:379–386
doi: 10.1016/S0140-6736(09)60737-6
Albain KS, Rusch VW, Crowley JJ et al (1995) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest oncology group phase II study 8805. J Clin Oncol 13:1880–1892
doi: 10.1200/JCO.1995.13.8.1880
van Meerbeeck JP, Kramer GW, Van Schil PE et al (2007) Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99(6):442–450
doi: 10.1093/jnci/djk093
Thomas M, Rübe C, Hoffknecht P et al (2008) Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 9(7):636–648
doi: 10.1016/S1470-2045(08)70156-6
Boffa D, Fernandez FG, Kim S et al (2017) Surgically managed clinical stage IIIA-clinical N2 lung cancer in the society of thoracic surgeons database. Ann Thorac Surg 104:395–403
doi: 10.1016/j.athoracsur.2017.02.031
Fernandez FG, Falcoz PE, Kozower BD et al (2015) The society of thoracic surgeons and the European society of thoracic surgeons general thoracic surgery databases: joint standardization of variable definitions and terminology. Ann Thorac Surg 99:368–376
doi: 10.1016/j.athoracsur.2014.05.104
Society of Thoracic Surgeons General Thoracic Surgery Database Training Manual: Version 2.3. Available at www.sts.org/sites/default/files/documents/August28_v2.3_GTSD_Training_Manual.pdf . Accessed 27 Aug 2018
European Society of Thoracic Surgery Annual Database Report (2016). Available at http://www.ests.org/_userfiles/pages/files/ESTS%202016Silver_Book_FULL_FINAL_14.50.pdf . Accessed 27 Aug 2018
Detterbeck FC, Boffa DJ, Tanoue LT (2009) The new lung cancer staging system. Chest 136:260–271
doi: 10.1378/chest.08-0978
Kozower BD, Sheng S, O’Brien SM et al (2010) STS database risk models: predictors of mortality and major morbidity for lung cancer resection. Ann Thorac Surg 90:875–883
doi: 10.1016/j.athoracsur.2010.03.115
Silvestri GA, Gonzalez AV, Jantz MA et al (2013) Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e211S – e250
doi: 10.1378/chest.12-2355
De Leyn P, Dooms C, Kuzdzal J et al (2014) Revised ESTS guidelines from preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg 45(5):787–798
doi: 10.1093/ejcts/ezu028
Ramnath N, Dilling TJ, Harris LJ et al (2013) Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e314S-e340S
doi: 10.1378/chest.12-2360
Brunelli A, Rocco G, Szanto Z et al (2020) Morbidity and mortality of lobectomy or pneumonectomy after neoadjuvant treatment; an analysis from the ESTS database. Eur J Cardiothorac Surg 57(4):740–746
doi: 10.1093/ejcts/ezz287
Yang CJ, Shah SA, Lin BK et al (2019) Right-sided versus left-sided pneumonectomy after induction therapy for non-small cell lung cancer. Ann Thorac Surg 107:1074–1081
doi: 10.1016/j.athoracsur.2018.10.009